Equillium, Inc. ("Equillium" or the "Company") (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat ...

Equillium stock is trading higher Monday after the company announced up to $50 million in financing through a securities ...

Equillium, Bluejay Diagnostics, and Entero Therapeutics are the 3 Penny Stocks to watch on August 12, 2025, based on TipRanks’ ...

Shares in the chipmaker were higher in pre-market trading as US president Donald Trump signalled he was open to working with ...

Equillium expects to begin enrolling patients in an alopecia areata Phase 2 study of EQ101 in the fourth quarter of 2022. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 ...

Investing.com -- Equillium Inc (NASDAQ: EQ) stock tumbled 12.4% after the biotechnology company announced plans to integrate cryptocurrency into its treasury reserve strategy, a significant deviation ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the completion of an End-of-Phase 1 meeting ...

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group ...

Access Equillium stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.